|
WO2021046155A1
|
|
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021041485A1
|
|
Controlled expression of viral proteins
|
|
WO2021030303A1
|
|
High-sensitivity immunoassay for the detection of frataxin in biofluids
|
|
WO2021030125A1
|
|
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
WO2021025995A1
|
|
Aav variants with enhanced tropism
|
|
WO2021016505A1
|
|
Compositions and methods for treating huntington's disease
|
|
WO2021007382A1
|
|
Compositions and methods for the treatment of parkinson's disease
|
|
WO2020227515A1
|
|
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
WO2020223296A1
|
|
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
WO2020223280A1
|
|
Aav variants with enhanced tropism
|
|
WO2020223279A1
|
|
VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
|
|
WO2020223276A1
|
|
Compositions and methods for the treatment of tauopathy
|
|
WO2020223274A1
|
|
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
TW202039858A
|
|
Methods and systems for producing aav particles
|
|
TW202028468A
|
|
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
|
WO2020077165A1
|
|
Compositions and methods for delivery of aav
|
|
WO2020072844A1
|
|
Engineered nucleic acid constructs encoding aav production proteins
|
|
TW202035689A
|
|
Methods for measuring the titer and potency of viral vector particles
|
|
WO2020072683A1
|
|
Redirection of tropism of aav capsids
|
|
CA3114621A1
|
|
Frataxin expression constructs having engineered promoters and methods of use thereof
|
